Uromigos Live 2023: Management of IO-Refractory RCC

During the second-annual Uromigos Live & Unplugged event, Thomas Powles, MBBS, MRCP, MD; Brian Rini, MD, FASCO; Toni Choueiri, MD; Sumanta Pal, MD, FASCO; and Tian Zhang, MD, highlight a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2, as well as their thoughts on the current role of IO-based therapy after prior IO.

Then, the panel move into a discussion of belzutifan and predict the results of this novel agent plus TKI in IO-refractory disease.

View the second kidney cancer session of the day on frontline metastatic disease.